Broad Institute

JULY 11, 2024

Targeted drug treatment leads tumor cells to imitate viral infection By Ari Navetta July 11, 2024 Breadcrumb Home Targeted drug treatment leads tumor cells to imitate viral infection Exploiting "viral mimicry," mIDH1 inhibitors trick tumors into thinking they are infected with a virus. paper cited Wu M, Kondo H, et al. Online July 11, 2024.

Treatment 72

Treatment Immune Response Drugs Virus 72

PerkinElmer

JULY 13, 2020

The complex relationship between a virus and its host is one of the hottest topics in science right now, and has been given considerable attention in recent weeks as a result of the race to understand the virus that causes COVID-19 and its potential vulnerabilities.

RNA 52

RNA Virus Laboratories Science 52

The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. About Molnupiravir.

Trials 69

Trials Virus RNA Research Laboratories 69

Drug Target Review

SEPTEMBER 28, 2023

They had the science and the technology but not the business model. For security reasons, at the time COVID-19 had to be grown in BSL-3 labs, which can be dangerous because they were handling the live virus. These are synthetic, not the live virus, so do not pose a risk of infection. Twist was officially founded in 2013.

DNA 116

DNA Organic Chemistry Science Virus 116

The Pharma Data

JANUARY 31, 2021

Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. About GlaxoSmithKline.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

DECEMBER 3, 2020

Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

OCTOBER 19, 2020

20, 2020 /PRNewswire/ — Caris Life Sciences® , a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that Winship Cancer Institute of Emory University (Winship) has joined Caris’ Precision Oncology Alliance (The Alliance/POA). . IRVING, Texas and ATLANTA , Oct.

Clinical Trials 52

Clinical Trials RNA DNA Science 52

The Pharma Data

JULY 6, 2021

But HIV’s ability to mutate isn’t unique among RNA viruses – most viruses develop mutations, or changes in their genetic code, over time. Changes in mutationally constrained epitopes are rare, as they can cause the virus to lose its ability to infect and replicate, essentially rendering it unable to propagate itself.

Vaccine 52

Vaccine Virus Research Immune Response 52

The Pharma Data

MARCH 9, 2022

Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two other targets. About Novartis.

Licensing 52

Licensing Licensing Therapies Disease 52

The Pharma Data

JANUARY 21, 2021

This was the first-ever, pre-approval implementation science study developed to evaluate ways to integrate Cabenuva into U.S. While much more remains to be done to make HIV history, today’s milestone reminds us how far medical innovation has come since the first reported cases of the virus almost 40 years ago.”. clinical practices.

FDA Approval 52

FDA Approval Treatment FDA Clinical Trials 52

The Pharma Data

JUNE 25, 2021

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. “We remain focused on being proactive as the virus evolves by leveraging the flexibility of our mRNA platform to stay ahead of emerging variants.” Moderna, Inc., This purchase brings the U.S.

Government 40

Government Vaccine RNA Science 40

Drug Target Review

SEPTEMBER 25, 2024

Analysis of transcriptional changes using RNA sequencing further confirmed that TT125-802 suppresses key non-oncogene resistance mechanisms including transcriptional networks around stemness, epithelial-mesenchymal transition (EMT), and transforming growth factor beta (TGFβ) signalling. Available from: [link] 9.Mohanty

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

The Pharma Data

JANUARY 6, 2021

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission has granted a conditional marketing authorization (CMA) for COVID-19 Vaccine Moderna, allowing vaccination programs using the Moderna vaccine to be rolled out across the European Union. About Moderna.

Vaccine 52

Vaccine FDA RNA Clinical Trials 52

The Pharma Data

JANUARY 12, 2021

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has authorized the COVID-19 Moderna Vaccine in Switzerland. Moderna has been named a top biopharmaceutical employer by Science for the past six years.

Vaccine 52

Vaccine RNA Clinical Trials Science 52

KIF1A

FEBRUARY 4, 2024

In addition to sequencing patients, the researchers looked for antibodies to the HTLV-1 virus in the patients’ spinal fluid. We each have two DNA copies of the KIF1A gene; each copy is called an allele and makes its own RNA, which is then translated into protein. What is an allele specific ASO?

RNA 52

RNA DNA Disease Trials 52

The Pharma Data

AUGUST 31, 2020

About the cobas HIV-1/HIV-2 Qualitative Test cobas HIV-1/HIV-2 Qualitative for use on the cobas 6800/8800 Systems is an in vitro nucleic acid amplification test for the qualitative detection and differentiation of human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) RNA in human serum and plasma. . Clin Infect Dis.

FDA Approval 52

FDA Approval FDA Virus Disease 52

The Pharma Data

SEPTEMBER 9, 2020

Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge. billion doses by the end of 2021.

Vaccine 52

Vaccine Clinical Trials RNA Trials 52

The Pharma Data

OCTOBER 21, 2020

The long-acting regimen of cabotegravir and rilpivirine is an investigational regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL). About ViiV Healthcare.

Clinical Development 52

Clinical Development Therapies Clinical Trials Treatment 52

Codon

JUNE 11, 2024

Their solution was to fuse hairpins, little loops made from RNA or DNA, at various positions along the DNA strand that was being sequenced. Now equipped with more serviceable proteins and clever methods to slow down DNA traffic, nanopores could finally evolve from a niche science project to an industrial sequencing workhorse.

DNA 87

DNA Engineering RNA Small Molecule 87

Alta Sciences

MARCH 1, 2024

q: How can Altasciences support sponsors’ Gene Therapy Programs? We have a supply of NHPs to ensure prompt study start. And more importantly, we have the facilities to screen large numbers of subjects and assign those that are negative to the adeno-associated viruses (AAVs) of interest to the study.

Therapies 52

Therapies Laboratories Molecular Biology RNA 52

The Pharma Data

SEPTEMBER 1, 2020

This can help healthcare professionals identify a SARS-CoV-2 infection in people suspected to carry the virus with results typically ready in 15 minutes. About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.

Virus 52

Virus Laboratories Clinical Trials Treatment 52

The Pharma Data

DECEMBER 19, 2020

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. Healthcare workers have been on the front lines of the fight against the virus and are an inspiration to us all. Moderna has been named a top biopharmaceutical employer by Science for the past five years.

Vaccine 52

Vaccine Long-Term Care Facilities FDA Licensing 52

Broad Institute

JUNE 27, 2024

Science (2024) Related content New gene delivery vehicle shows promise for human brain gene therapy My Quest to Cure Prion Disease — Before It’s Too Late | Sonia Vallabh | TED Prion diseases lead to rapid neurodegeneration and death and are caused by misshapen versions of the prion protein in the brain. Credit: Neumann EN, Bertozzi TM, et al.

Disease 142

Disease Therapies Clinical Trials Engineering 142

The Pharma Data

JULY 29, 2021

Gilead Sciences, Inc. Our flagship HIV therapy, Biktarvy, saw continued growth and gains in market share, despite the ongoing impact of the pandemic,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. econd Quarter 2021 Product Sales Increased 21% Year-Over-Year Primarily Driven by Veklury. Viral Diseases.

Science 52

Science Production Treatment FDA Approval 52

The Pharma Data

JANUARY 21, 2021

Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. 50 c/mL, meeting noninferiority criteria.

FDA Approval 52

FDA Approval Treatment RNA FDA 52

PLOS: DNA Science

JUNE 13, 2024

Ruling Out Alternate Explanations Requires Logic and Science Soon after Fauci’s grilling, Alina Chan, a molecular biologist at the Broad Institute of MIT and Harvard, succinctly explained the converging evidence in a compelling Opinion piece in the June 9 New York Times. An altered virus could have escaped. Her points: 1.

Virus 52

Virus RNA DNA Science 52

Broad Institute

DECEMBER 6, 2023

Using single-cell RNA sequencing to analyze gene expression in individual cells, the researchers have found how 86 major cytokines affect 17 immune cell types in mice. Tags: Cell Circuits Program Immunology RNA sequencing The reference, called the Immune Dictionary , appears today in Nature. Paper cited Cui A et al.

Immune Response 138

Immune Response RNA Disease Medical Schools 138

Drug Target Review

SEPTEMBER 4, 2023

Infectious agent includes bacteria, virus, fungi, and parasites, and they are capable of causing disease in a living organism. I had earlier proposed the use of Palmatine and Silver Nitrate in the efficacy against the RNA structure of the COVID-19 virus. We discovered it is highly effective and environmentally friendly.

Drugs 111

Drugs RNA DNA Disease 111

Codon

JUNE 25, 2024

Due to the nearly ubiquitous use of cloning in life science research, this lost time adds up. Proteins are colored blue and RNA molecules are colored orange and yellow. RNA and proteins comprise each ribosome, but the cell synthesizes these two biomolecules at different rates. The large and small ribosome subunits.

DNA 82

DNA RNA Laboratories Research 82

Codon

MARCH 20, 2023

Basic Science A trailing ribosome speeds up RNA polymerase at the expense of transcript fidelity via force and allostery. Science Advances. Science Advances. Ribozyme-mediated RNA synthesis and replication in a model Hadean microenvironment. Assembly of metabolons in yeast using Cas6-mediated RNA scaffolding.

Virus 52

Virus Engineering RNA Small Molecule 52

The Pharma Data

OCTOBER 21, 2020

The COVID-19 pandemic has highlighted the urgent need for a novel, oral antiviral to treat this highly infectious and often deadly virus,” said Jean-Pierre Sommadossi, Ph.D., “Roche shares our passion for delivering innovative new medicines to address great unmet medical needs. Chief Executive Officer and Founder of Atea Pharmaceuticals.

RNA 52

RNA Pharmaceuticals Virus Clinical Trials 52

Codon

APRIL 2, 2023

Basic Science *No evidence for a common blood microbiome based on a population study of 9,770 healthy humans. Read A new DNA polymerase variant, called RT-KTq I614Y, can directly detect RNA modifications, including pseudouridine (Ψ) and queuosine (Q). Massively parallel profiling of RNA-targeting CRISPR-Cas13d.

DNA 52

DNA RNA Engineering Licensing 52

Drug Target Review

MARCH 21, 2024

Because mRNA is not a virus, it doesn’t have to meet biosafety requirements for manufacturing and administration that an AAV approach would need. Additionally, the COVID-19 RNA vaccines have already demonstrated how safe RNA can be, and we look forward to seeing additional safety data on RNA approaches as the field continues to grow.

Therapies 64

Therapies RNA Immune Response Treatment 64

Broad Institute

AUGUST 11, 2022

The study appears in Science. Two viral proteins elicited an immune response: the portal, a part of the virus’s capsid shell, which contains viral DNA; and the terminase, the molecular motor that helps assemble the virus by pushing the viral DNA into the capsid. The cells underwent a dramatic defensive response and survived.

DNA 52

DNA Virus Immune Response Bioinformatics 52

Broad Institute

MAY 14, 2024

William Studier for development of widely used protein- and RNA-production platform By Corie Lok May 14, 2024 Breadcrumb Home Merkin Prize in Biomedical Technology awarded to F. Merkin Prize in Biomedical Technology for his development of an efficient, scalable method of producing RNA and proteins in the laboratory.

RNA 84

RNA Production Molecular Biology Laboratories 84

The Pharma Data

FEBRUARY 25, 2022

“There remains an urgent need for SARS-CoV-2 therapeutic agents that target parts of the virus other than the spike protein that are not as likely to evolve.” “In cell culture, we showed that if you combine Mpro and PLpro inhibitors, you have a stronger effect on the virus without increasing toxicity,” said Jose.

FDA Approval 52

FDA Approval FDA Molecular Biology Virus 52

The Pharma Data

NOVEMBER 1, 2021

Rice University researchers have introduced an online portal to help researchers screen COVID-19 drug candidates that might attack specific proteins of the SARS-CoV-2 virus. Understanding these structures allows researchers to find binding partners that could, ideally, deactivate the virus.

Virus 52

Virus RNA Drugs Engineering 52